Multiple myeloma and peptides — the proteasome-inhibitor peptide-pharmacophore class, the bone-disease comorbidity, and the modern triplet-quadruplet sequencing

Why this dossier exists

Multiple myeloma is the malignancy where peptide pharmacology became the therapeutic backbone of the modern treatment paradigm — not through endogenous-peptide replacement or growth-axis modulation, but through three peptide-pharmacophore small-molecule drugs that engage the 20S proteasome chymotrypsin-like β5 catalytic site through a recognized peptide backbone plus a C-terminal warhead. Bortezomib is a dipeptidyl boronate, carfilzomib is a tetrapeptide epoxyketone, and ixazomib is an orally bioavailable boronate dipeptide; the molecular feature unifying the class is a short oligopeptide chain that mimics protein substrates entering the proteasome's catalytic tunnel, anchoring the inhibitor in the active site while the warhead executes the reversible (boronate) or irreversible (epoxyketone) covalent attack. The result is a peptide-pharmacophore drug class that has rewritten plasma-cell-cancer survival curves over two decades. The full pharmacology of the class lives on the proteasome inhibitor class entry; this dossier walks the surrounding clinical context — the disease the class treats, the bone-disease comorbidity that brings the anabolic and antiresorptive peptide-and-protein osteoporosis class into the differential, and the practical sequencing question that defines modern frontline regimens.

Multiple myeloma is a monoclonal plasma cell neoplasm characterized by clonal proliferation of malignant plasma cells in the bone marrow, monoclonal immunoglobulin secretion ("M-protein") in serum or urine, and end-organ damage captured by the CRAB criteria (hyperCalcemia, Renal insufficiency, Anemia, Bone lesions). The American Cancer Society reported 35,730 estimated new US cases for 2023, accounting for ~1.8% of new cancer diagnoses, with SEER projecting 36,110 new cases for 2025 — a steady incidence climb across the 1999–2024 period running alongside falling mortality as therapy has improved. The disease evolves through a recognized continuum: monoclonal gammopathy of undetermined significance (MGUS) → smoldering multiple myeloma (SMM) → active (symptomatic) multiple myeloma. The Mayo Clinic SMM natural-history cohort published in Kyle RA, Remstein ED, Therneau TM et al., N Engl J Med 2007, 356(25):2582–2590 established that smoldering myeloma progresses to active disease or amyloidosis at ~10% per year for the first 5 years, 3% per year over years 5–10, and 1–2% per year thereafter — the 20-year cumulative progression risk approaching 80%. The 2014 IMWG diagnostic criteria update Rajkumar SV, Dimopoulos MA, Palumbo A et al., Lancet Oncol 2014, 15(12):e538–e548 added three biomarker criteria — ≥60% clonal bone marrow plasma cells, involved-to-uninvolved serum free light chain ratio ≥100 with involved FLC ≥100 mg/L, and >1 focal lesion ≥5 mm on MRI — that permit diagnosis of active myeloma in patients who do not yet have CRAB features, formalizing earlier intervention in patients destined for end-organ damage.

The plasma cell is a uniquely proteasome-dependent cell. Differentiation into an antibody-secreting plasma cell drives massive immunoglobulin synthesis through the endoplasmic reticulum, and the resulting misfolded-protein burden saturates the ER quality-control machinery; the ubiquitin–proteasome system handles much of the disposal load. Plasma cells live near the ceiling of their proteasome capacity even in healthy biology; in the malignant clone, monoclonal-immunoglobulin synthesis pushes the ratio of proteasome workload to proteasome supply higher still. Proteasome inhibition tips that ratio into terminal proteotoxic stress — accumulating ubiquitinated substrates, activating the unfolded protein response, triggering NF-κB suppression, and ultimately inducing apoptosis preferentially in the malignant plasma cell rather than in normal hematopoietic, epithelial, or immune cells. The peptide-pharmacophore drugs exploit this asymmetry. The clinical readouts that follow — APEX, VISTA, ASPIRE, ENDEAVOR, TOURMALINE — are the empirical confirmation of the mechanism.